Tempus AI Shares Climb After Rollout of HRD-RNA Cancer Detection Tool
Tempus AI, Inc. (NASDAQ:TEM) saw its stock rise 3.5% Wednesday following the announcement of HRD-RNA, a 1,660-gene logistic regression algorithm that evaluates Homologous Recombination Deficiency via tumor gene expression rather than DNA scarring. The algorithm is available for research use now, with clinical availability expected later this year. …